Fenofibrate works in women as well as men
In 2010, results from the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial suggested a gender disparity in the effectiveness of fenofibrate treatment in type 2 diabetes, with a subgroup analysis signalling possible harm in women.
This is challenged by latest results from the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study, reported in Diabetologia (online, 18 August 2014). A pre-specified analysis found that cardiovascular event reductions with fenofibrate are consistently similar in women and men and that fenofibrate improves the lipoprotein profile more in women than men.
“These data provide reassurance about fenofibrate efficacy in women and men,” write the FIELD researchers, led by Anthony Keech, from the University of Sydney, Australia. “Both sexes with type 2 diabetes should be considered for fenofibrate therapy for cardioprotection.”
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066240
Recommended from Pharmaceutical Press
All you need to know about prescribing or administering drugs via enteral feeding tubes. Over 400 drug monographs as well as facts to inform clinical decision making.£54.00Buy now
Standards for unlicensed aseptic preparation in the UK, as well as practical information for implementing the standards.£46.00Buy now